Stock IKNA IKENA ONCOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Ikena Oncology, Inc.

Equities

IKNA

US45175G1085

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 18:42:03 29/04/2024 BST 		5-day change 1st Jan Change
1.3 USD 0.00% Intraday chart for Ikena Oncology, Inc. 0.00% -34.01%
03-12 Ikena Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-12 North American Morning Briefing : Inflation Data -2- DJ

Business Summary

Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The Company's lead targeted oncology program, IK-930, is a transcriptional enhanced associate domain 1 (TEAD1) selective Hippo pathway inhibitor, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company's second clinical-stage program targets the RAS signaling pathway with IK-595, a novel MEK-RAF molecular glue. It has IK-175 aryl hydrocarbon receptor (AHR) antagonist program that completed Phase 1 clinical trial. Its partnering portfolio also includes several other immune oncology programs that are available for potential sale or outlicensing, including PY314, a Phase 2 ready TREM2 antagonist, PY159, a Phase 2 ready TREM1 antagonist, and PY265, an IND-ready MARCO antagonist.

Number of employees: 43

Sales per Business

USD in Million2022Weight2023Weight Delta
Novel Cancer Therapies
100.0 %
16 100.0 % 9 100.0 % -41.35%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
16 100.0 % 9 100.0 % -41.35%

Managers

Managers TitleAgeSince
Mark Manfredi FOU
 Founder 53 31/01/16
Jotin Marango DFI
 Director of Finance/CFO 45 24/04/22
Caroline Germa CTO
 Chief Tech/Sci/R&D Officer 52 02-28
Michelle Zhang CTO
 Chief Tech/Sci/R&D Officer - 31/12/15
Rebecca Cohen IRC
 Investor Relations Contact - -
Samantha Vuksanic HRO
 Human Resources Officer - 31/05/21
Jeffrey Ecsedy PRN
 Corporate Officer/Principal 54 30/09/17

Members of the board

Members of the board TitleAgeSince
Jean-Francois Formela BRD
 Director/Board Member 67 29/02/16
David Bonita BRD
 Director/Board Member 48 -
Otello Stampacchia BRD
 Director/Board Member 55 30/11/20
Iain Dukes BRD
 Director/Board Member 65 31/10/16
Owen Hughes CHM
 Chairman 49 14/12/22
Richard Wooster BRD
 Director/Board Member 59 20/01/22
Mark Manfredi FOU
 Founder 53 31/01/16
Maria Koehler BRD
 Director/Board Member 67 14/04/21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 41,889,525 38,958,058 ( 93.00 %) 0 93.00 %
Stock B 0 4,153,439 0 0

Shareholders

NameEquities%Valuation
OrbiMed Advisors Private Equity
20.53 %
9,907,945 20.53 % 14 M $
Atlas Venture Life Science Advisors LLC
10.40 %
5,018,178 10.40 % 7 M $
BVF, Inc.
9.883 %
4,769,164 9.883 % 7 M $
Fidelity Management & Research Co. LLC
8.671 %
4,184,293 8.671 % 6 M $
GILEAD SCIENCES, INC.
6.075 %
2,931,467 6.075 % 4 M $
Omega Fund Management LLC
4.661 %
2,249,123 4.661 % 3 M $
CHI Advisors LLC
4.519 %
2,180,934 4.519 % 3 M $
Blue Owl Healthcare Opportunities Advisors LLC
4.048 %
1,953,616 4.048 % 3 M $
BlackRock Advisors LLC
3.714 %
1,792,128 3.714 % 3 M $
Vanguard Fiduciary Trust Co.
3.160 %
1,524,848 3.160 % 2 M $
NameEquities%Valuation
OrbiMed Advisors Private Equity
100.00 %
6,368,587 100.00 % 9 M $
NameEquities%Valuation
OrbiMed Advisors Private Equity
8.504 %
353,192 8.504 % 501 533 $

Company contact information

Ikena Oncology, Inc.

645 Summer Street Suite 101

02210, Boston

+

http://www.ikenaoncology.com
address Ikena Oncology, Inc.(IKNA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Ikena Oncology, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.3 USD
Average target price
8.333 USD
Spread / Average Target
+541.03%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IKENA ONCOLOGY, INC. Stock Ikena Oncology, Inc.
-34.01% 62.74M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+2.73% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+47.70% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+11.98% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-8.83% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.73% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.70% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.71% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.73% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+9.40% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. IKNA Stock
  4. Company Ikena Oncology, Inc.